According to reports, Belanger is a believer in Ocular mainly on the potential of its investigational Axpaxli, a drug that ...

Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand ...

Eye diseases often develop asymptomatically for many years. ICTER scientists have developed the f-ORG technique, which ...

Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse ...

While it is easier to advise people to not sit for long hours in front of their screens, for those who work on a computer, it is a difficult task to achieve. Sitting for a prolonged time in front of ...

Good vision and overall eye health depend on a combination of lifestyle choices and a balanced diet rich in essential ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an ...

Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.

Certified AI management practitioner and AI strategy advisor at Techstars Jess Jeetley, who was once a practising optometrist, discusses how AI could be integrated into healthcare ...

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...